Pfizer has garnered another US Food and Drug Administration biosimilar approval, receiving a nod from the agency for its Ruxience (rituximab-pvvr) rival to Genentech’s Rituxan original.
The approval marks the third oncology monoclonal antibody (mAb) biosimilar nod from the FDA this year for Pfizer, after Trazimera...






